239 related articles for article (PubMed ID: 28949463)
1. Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies.
Lehoux P; Miller FA; Daudelin G; Denis JL
Int J Health Policy Manag; 2017 Sep; 6(9):509-518. PubMed ID: 28949463
[TBL] [Abstract][Full Text] [Related]
2. New Health Technologies: A UK Perspective Comment on "Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies".
Parvizi N; Parvizi S
Int J Health Policy Manag; 2017 Dec; 6(12):721-722. PubMed ID: 29172379
[TBL] [Abstract][Full Text] [Related]
3. The Conceptualization of Value in the Value Proposition of New Health Technologies Comment on "Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies".
Buttigieg SC; Hoof JV
Int J Health Policy Manag; 2018 Feb; 7(2):186-188. PubMed ID: 29524943
[TBL] [Abstract][Full Text] [Related]
4. The Bright Elusive Butterfly of Value in Health Technology Development Comment on "Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies".
Greenhalgh T; Fahy N; Shaw S
Int J Health Policy Manag; 2018 Jan; 7(1):81-85. PubMed ID: 29325407
[TBL] [Abstract][Full Text] [Related]
5. A regulatory governance perspective on health technology assessment (HTA) in France: the contextual mediation of common functional pressures.
Barron AJ; Klinger C; Shah SM; Wright JS
Health Policy; 2015 Feb; 119(2):137-46. PubMed ID: 25458970
[TBL] [Abstract][Full Text] [Related]
6. Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.
Calabrò GE; La Torre G; de Waure C; Villari P; Federici A; Ricciardi W; Specchia ML
BMC Health Serv Res; 2018 Mar; 18(1):148. PubMed ID: 29490647
[TBL] [Abstract][Full Text] [Related]
7. A comparative analysis of non-invasive prenatal testing in Ontario and Quebec: the role of governing style in health technology innovation & adoption.
Saleh L; Parker G; Stevenson M; Miller FA
BMC Health Serv Res; 2023 Mar; 23(1):231. PubMed ID: 36890546
[TBL] [Abstract][Full Text] [Related]
8. Investors prefer entrepreneurial ventures pitched by attractive men.
Brooks AW; Huang L; Kearney SW; Murray FE
Proc Natl Acad Sci U S A; 2014 Mar; 111(12):4427-31. PubMed ID: 24616491
[TBL] [Abstract][Full Text] [Related]
9. A regulatory governance perspective on Health Technology Assessment (HTA) in Sweden.
Shah SM; Barron A; Klinger C; Wright JS
Health Policy; 2014 May; 116(1):27-36. PubMed ID: 24655685
[TBL] [Abstract][Full Text] [Related]
10. Modes of coordination for health technology adoption: Health Technology Assessment agencies and Group Procurement Organizations in a polycentric regulatory regime.
Miller FA; Lehoux P; Rac VE; Bytautas JP; Krahn M; Peacock S
Soc Sci Med; 2020 Nov; 265():113528. PubMed ID: 33261901
[TBL] [Abstract][Full Text] [Related]
11. Enabling health technology innovation in Canada: Barriers and facilitators in policy and regulatory processes.
MacNeil M; Koch M; Kuspinar A; Juzwishin D; Lehoux P; Stolee P
Health Policy; 2019 Feb; 123(2):203-214. PubMed ID: 30352755
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis and innovation.
Jena AB; Philipson TJ
J Health Econ; 2008 Sep; 27(5):1224-36. PubMed ID: 18619695
[TBL] [Abstract][Full Text] [Related]
13. [Quality of health care, accreditation, and health technology assessment in Croatia: role of agency for quality and accreditation in health].
Mittermayer R; Huić M; Mestrović J
Acta Med Croatica; 2010 Dec; 64(5):425-34. PubMed ID: 21692267
[TBL] [Abstract][Full Text] [Related]
14. The role of health technology assessment in the comprehensive evaluation of the impact of immunotherapy on real practice.
Frati F; Ariano R; Cadario G; Ortolani C; Passalacqua G
Eur Ann Allergy Clin Immunol; 2007; 39 Spec No():4-6. PubMed ID: 18924459
[TBL] [Abstract][Full Text] [Related]
15. How does venture capital operate in medical innovation?
Lehoux P; Miller FA; Daudelin G
BMJ Innov; 2016 Jul; 2(3):111-117. PubMed ID: 27547447
[TBL] [Abstract][Full Text] [Related]
16. Physician entrepreneur: lessons learned in raising capital for biomedical innovation.
Soleimani F; Kharabi DG
Curr Opin Anaesthesiol; 2010 Apr; 23(2):209-17. PubMed ID: 20173634
[TBL] [Abstract][Full Text] [Related]
17. Early assessment of medical technologies to inform product development and market access: a review of methods and applications.
Ijzerman MJ; Steuten LM
Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163
[TBL] [Abstract][Full Text] [Related]
18. Historical development of health technology assessment in Thailand.
Teerawattananon Y; Tantivess S; Yothasamut J; Kingkaew P; Chaisiri K
Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():241-52. PubMed ID: 19527543
[TBL] [Abstract][Full Text] [Related]
19. Translating Orthopaedic Technologies Into Clinical Practice: Challenges and Solutions.
Maher SA; Kyle R; Morrey BF; Yaszemski MJ
J Am Acad Orthop Surg; 2019 Jan; 27(1):e9-e16. PubMed ID: 30320732
[TBL] [Abstract][Full Text] [Related]
20. The decline of venture capital investment in early-stage life sciences poses a challenge to continued innovation.
Fleming JJ
Health Aff (Millwood); 2015 Feb; 34(2):271-6. PubMed ID: 25646107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
